Table 2.
Disease characteristics of the patients in these studies.
| Author | Stage (numbers) | Serous | Mixed | LVI (percent of cases) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 1A | 1B | 1C | Total | + | − | Unknown | |||
| Bancher-Todesca et al. [42] | 1 | 1 | 1 | 3 | — | — | — | — | — |
| Bristow et al. [28] | 4 | 7 | — | 10 | — | — | — | — | — |
| Carcangiu et al. [33] | 13 | — | — | 13 | — | — | — | — | — |
| Dietrich et al. [34] | 7 | 17 | 5 | 29 | 16 | 5 | — | — | — |
| Elit et al. [35] | 22 | 13 | 8 | 43 | 36 83% |
7 17% |
— | — | — |
| Fader et al. [36–38] | 51 | 65 | 26 | 142 | — | — | — | — | — |
| Fields et al. [32] | 2 | 12 | 2 | 16 | — | — | — | — | — |
| Gallion et al. [22] | 3 | 5 | 3 | 11 | — | — | 7 64% |
4 36% |
— |
| Gehrig [44] | 6 | — | — | 6 | — | — | 5 83% |
1 17% |
— |
| Grice et al. [43] | 4 | 4 | 4 | 12 | — | — | — | — | — |
| Huh et al. [29] | 19 | 26 | 15 | 60 | 51 85% |
10 15% |
— | — | — |
| Havrilesky et al. [39] | 32 | 34 | 16 | 82 | — | — | 18 22% |
54 65% |
11 13% |
| Kelly et al. [40] | 33 | 29 | 12 | 74 | 47 64% |
27 36% |
— | — | — |
| Low et al. [45] | 1 | 6 | 2 | 9 | — | — | — | — | — |
| Piura et al. [46] | 1 | 3 | 3 | 7 | — | — | — | — | — |
| Slomovitz et al. [47] | 19 | 26 | 7 | 52 | 27 56% |
23 44% |
12 23% |
40 77% |
— |
| Thomas et al. [41] | 15 | 21 | 6 | 42 | — | — | — | — | — |
| Elit et al.* | 6 | 10 | 5 | 21 | 19 90% |
2 10% |
3 14% |
18 86% |
— |
|
| |||||||||
| TOTAL | 233 | 269 | 110 | 611 | 177/258 69% |
72/258 28% |
42/151 28% |
99/151 66% |
11/82 13% |
*Data from Elit are not added to summary statistics as median followup is less than 24 months.